



## **Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets**

SAN CARLOS, Calif., April 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: <http://www.nektar.com>. The web broadcast of the conference call will be available for replay through Wednesday, May 20, 2009.

To access the conference call, follow these instructions:

Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)  
Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

### About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at <http://www.nektar.com>

Jennifer Ruddock, 650-631-4954, Nektar Therapeutics

SOURCE Nektar Therapeutics

<http://www.nektar.com>

Copyright (C) 2009 PR Newswire. All rights reserved